News

Covi-TRaC: arming our immune cells against SARS-COV2

September 11, 2020

Prolific for researchers, the confinement period has allowed the French Establishment of Blood’s (EFS) teams to give birth to and mature many ideas from pre-existing studies. About fifteen projects were submitted to the national EFS as part of the anti-covid research program. A team from Besançon was thus allocated dedicated seed funding for their project considered as a priority - 3 in total were selected.

Contrary to calls for proposals, particularly European ones, launched in the midst of a crisis and calling for immediate applications (production of masks, hydroalcoholic solutions, etc.), this work carried out within the EFS Bourgogne-Franche-Comté (Besançon) aims to identify immune cells that recognize the virus in order to be able to provide medical applications in the medium and long term.

Marina Deschamps and Christophe Ferrand, both researchers at the Right Institute (UMR 1098) and the EFS, have used their twenty years of experience in the field of antitumor cell immunotherapy and CAR-T cells to imagine a process adapted to the treatment of COVID-19.

Their Covi-TRaC project consists of isolating T-lymphocytes so that they can be reprogrammed, armed and used against cells infected with SARS-COV2. The research is being conducted in support of the Coviplasm trial and other EFS teams.

How does it work?

Every person is born with a pool of basic immune cells that we educate throughout our lives: some people are therefore armed to react to the virus and develop adapted "T receptors".

The Coviplasm project collects plasma from these convalescent patients to study it for therapeutic purposes. Using these samples, Covi-TRaC isolates the T-lymphocytes present in the blood to identify the genes that have recognized the disease, using molecular biology technologies. These genes are then transferred to "naïve" T-cells to gain recognition of the disease and kill the infected cell.

"This is a technique we've been using for a long time in the field of CAR-T cells," explain the two researchers, who almost obviously "adapted their research to a new target", this time viral rather than tumoural.

This process should yield good results, especially for immunocompromised patients, for whom a vaccine would not be applicable.

What are the results?

The research carried out within Covi-TRaC has a twofold interest: therapeutic but primarily scientific, since it provides a better understanding of the deregulation of the immune system caused by the virus.

Indeed, the application of this type of research up to the production of a treatment is very long. Marina Deschamps insists "we all necessarily want to be able to provide new options for patients, but we don't have miracle solutions". And yet, by helping to understand the disease and how it works, they are contributing to the knowledge that is shared worldwide.

News

Tebubio : A complete range of solutions to optimize all your Biomanufacturing projects.

October 09, 2023

Since 1953, Tebubio facilitates Life Sciences research in France and throughout Europe. With over 80 team members across Europe, we provide researchers with a range of innovative solutions in many...

Learn more

Tebubio Laboratory : Access a personalized mini-scale mRNA production service

October 09, 2023

In response to the growing need for mRNA, Tebubio’s laboratories offer a mini-scale mRNA production service to quickly provide you with customised and optimised research grade sequences to be used...

Learn more

Microsynth France Le laboratoire de séquençage Sanger à Lyon

July 04, 2023

Learn more

Proteintechs GMP growth factors manufacturing facility, Chicago

July 04, 2023

Proteintech is a leading manufacturer of antibodies, immunoassays, proteins and Nanobodies. Overview of the Proteintech product range:  Antibodies against 13,000+ human targets. Trial size versions available.  Immunoassay kits...

Learn more

Myltenyi Biotech – New modules to expand processing capabilities of the CliniMACS Prodigy® Platform: electroporation and final formulation.

June 20, 2023

Learn more

Miltenyi Biotech – New automated process to simplify the manufacturing of gene-engineered NK Cells and Clinical-grade tumor-reactive T cell

June 20, 2023

The CliniMACS Prodigy® Tumor Reactive T (TRT) Cell Process offers a new, adaptable platform for scientists and clinicians working on tumor-infiltrating leukocyte (TIL) therapy, and can be tailored to the...

Learn more

Lumicks – Cell avidity: a new predictor of immune cell function and therapeutic success

June 20, 2023

Affinity between chimeric antigen receptor (CAR) T cells and their target have shown to be a poor predictor for T-cell function. On the contrary, cell avidity (or overall cellular binding...

Learn more

Miltenyi : New modules to expand processing capabilities of the CliniMACS Prodigy® Platform: electroporation and final formulation

August 05, 2022

The CliniMACS Prodigy represents the next generation in automated cell processing. This device offers advanced integrated solutions to streamline cell processing workflows – from cell separation through cell culture to...

Learn more

Gilson is pleased to partner with Syngoi Technologies to equip their latest GMP facility

August 04, 2022

We are pleased to announce that Gilson Connect solutions have been selected by Syngoi Technologies to enforce the traceability and repeatability of manual protocols. Syngoi Technologies is a biotechnology company...

Learn more

Gilson is pleased to partner with France Blood Transfusion Agency (EFS) Platform for Innovation in Biotherapies

August 03, 2022

Gilson is pleased to announce a new chapter of collaborating with the EFS Gene and Cell engineering unit of Bourgogne Franche Comté. The collaboration provides the EFS Development & Transfer...

Learn more

New automated process to simplify the manufacturing of gene-engineered NK Cells and Treg cells isolation

July 28, 2022

To address the variety of Treg cell applications, Miltenyi Biotec provides a broad range of tools for clinical use.

Learn more

CREAPHARM DEMONSTRATES UNPARALLELED PERFORMANCE OF -80°C NITROGEN TANK TECHNOLOGY

July 28, 2022

CREAPHARM BIOSERVICES has recently invested in -80°C nitrogen tanks to provide Biotechs and Research key players with a new solution to meet the challenges of ultra-low temperature storage.

Learn more

Videodrop, an ideal tool for the monitoring of bioproduction of Viral vectors

July 19, 2022

Today, Gene and Cell therapies are booming. However, due to the lack of solutions allowing rapid & continuous monitoring throughout the bioproduction process, Biotech’ companies are working “almost blind”. They...

Learn more

Measuring Size & concentration of nanoparticles

July 19, 2022

The Videodrop makes it possible to measure the size and concentration of biological nanoparticles like lentivirus, adenovirus or retrovirus

Learn more

Cytiva and Bayer to collaborate on allogeneic cell therapy manufacturing platform

July 12, 2022

Learn more

Article on improving viral vector production in GEN

July 12, 2022

GEN recently interviewed our Business Development Director, Dr. Natalia Elizalde, with whom they spoke about improving the production of lentiviral vectors, vectors that VIVEbiotech develops and manufactures.

Learn more

Cytiva and Nucleus Biologics join forces to accelerate development of custom cell media for cell and gene therapies

July 07, 2022

Cytiva, a global life sciences leader, and Nucleus Biologics, LLC, The Cell Performance Company™, have signed a collaboration agreement on custom media formulation and fulfillment solutions for the cell and...

Learn more

PharmaBoardoom points out VIVEbiotech as one of the ten Spanish Biotechs to watch in 2022

July 05, 2022

PharmaBoardroom, a leading British media specialized in the health sector, has published an article in which it highlights VIVEbiotech as one of the ten Spanish biotechs to follow in 2022.

Learn more

The Analytical Scientist interviews Rakel Lopez de Maturana

June 28, 2022

The Analytical Scientist interviewed Rakel Lopez de Maturana, VIVEbiotech´s Qualified Person & Regulatory Affairs Director.

Learn more

Gurutz Linazaroso, the CEO of VIVEbiotech, in the Medicine Maker Power List 2022

June 21, 2022

The CEO of VIVEbiotech, Dr. Gurutz Linazasoro, is part of the prestigious The Medicine Maker Power List.

Learn more

Interview with Natalia Elizalde in The Medicine Maker

June 14, 2022

The Business Development Director of VIVEbiotech Dr. Natalia Elizalde was interviewed by The Medicine Maker on the challenges of lentiviral vector manufacture/use.

Learn more

Plasmid DNA manufacturing – Soon a GMP Grade unit in TEMIS Santé, Besançon – Fr

April 19, 2022

Learn more

Landau Partnership

September 22, 2021

VectorBuilder Inc., a global leader in vector design, optimization and GMP manufacturing, and Landau Biotechnology Co., a world leader in developing nonhuman primate (NHP) models for clinical research applications, have...

Learn more

Univercells Partnership

September 16, 2021

VectorBuilder – a global leader in vector design, optimization, and GMP manufacturing – has formed a worldwide strategic partnership with Univercells Technologies, a provider of novel biomanufacturing technologies for flexible...

Learn more

The MACSima™ Imaging Platform is the only complete solution for ultra high content imaging experiments.

September 13, 2021

Learn more

New automated process to simplify the manufacturing of gene-engineered hematopoietic stem cells with the CliniMACS Prodigy® HSC Engineering System

September 13, 2021

Learn more

MedXCell SA

August 25, 2021

MedXCell Science SA: MedXCell Science SA was co-founded in 2018 by the University Hospital of Montpellier (CHU of Montpellier) in France and the Swiss company MedXCell SA. It was the...

Learn more

Cryoport Systems now supporting 7 commercial therapies globally

July 27, 2021

Learn more

Polyplus-transfection initiates construction of Vectura, a new 4,000m2 facility

July 23, 2021

Learn more

Polyplus-transfection® launches FectoVIR®-AAV

July 23, 2021

Learn more

RD-Biotech: a new company from Besançon wins the « France Relance » call for projects

February 22, 2021

Following the unprecedented health crisis and its unprecedented economic impact, the Government has put in place numerous tools to support businesses.

Learn more